Dostinex, the brand name for cabergoline, is a dopamine receptor agonist used to treat hyperprolactinemia, characterized by elevated prolactin levels in the blood. It is primarily indicated for managing prolactinomas (prolactin-secreting pituitary tumors), restoring normal menstrual cycles in women experiencing amenorrhea due to high prolactin, and addressing infertility linked to hyperprolactinemia. Cabergoline effectively lowers prolactin levels, normalizing them in a significant percentage of patients, and is often better tolerated than other treatments like bromocriptine, requiring less frequent dosing due to its long-acting nature.